Business
Launch of a capital increase with preferential subscription rights for nearly 5 million euros
Press release Launch of a capital increase with preferential subscription rights for nearly 5 million euros Issuance of new shares for an initial total amount of around €5.0 million, with shareholders maintaining their preferential subscription rights (DPS), which may be increased to around €5.7 million if the extension clause is exercised (the “Offer”).Intentions and commitment to subscribe by existing shareholders and Vatel Capital, as a new institutional investor, for a total amount of approx
About this update from Crossject Sa
[{"type":"image","alt":"CROSSJECT","displaySize":"","headline":null,"caption":"CROSSJECT","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/5049eda363ac301cbfd1577dab53d65a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rK9m607pcnIrkhBB4D_IFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5049eda363ac301cbfd1577dab53d65a","width":200,"height":87}},"lazy":false},{"type":"text","content":"Press release","length":13,"tagName":"p"},{"type":"text","content":"Launch of a capital increase with preferential subscription rights for nearly 5 million euros","length":93,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Issuance of new shares for an initial total amount of around €5.0 million, with shareholders maintaining their preferential subscription rights (DPS), which may be increased to around €5.7 million if the extension clause is exercised (the “Offer”).","length":248,"tagName":"p"}]},{"val":[{"type":"text","content":"Intentions and commitment to subscribe by existing shareholders and Vatel Capital, as a new institutional investor, for a total amount of approximately 3.7M€, already representing 76,4% of the transaction.","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Subscription price for the new shares set at €1.40, representing a 22.6% discount to the closing price of the CROSSJECT share on June 3, 2025 (€1.808) and a 21.3% discount to the theoretical value of the CROSSJECT share ex-rights.","length":230,"tagName":"p"}]},{"val":[{"type":"text","content":"Subscription period from June 12, 2025 to June 20, 2025 included.","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":748,"olType":false},{"type":"text","content":"Dijon, France 4 June 2025 (8.10 PM CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration of ZEPIZURE®, launches a capital increase with preferential subscription rights (“DPS”), for an initial total amount of 4,978,678.60 euros (“the Offer”), which may be increased to 5,725,479.20 euros if the extension clause is exercised.","length":407,"tagName":"p"},{"type":"text","content":"Objectives of the capital increase","length":34,"tagName":"p"},{"type":"text","cont...